Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 Commitment is part of the European ...

IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing More on IO Biotech IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant ...

IO Biotech's lead candidate, IO102, is an IDO-derived immune modulating therapy with a dual mode of action - killing both cancer and immune-suppressive cells.

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ...

(RTTNews) - Shares of IO Biotech, Inc. (IOBT) are up more than 21% on Friday at $10.05. There have been no company-specific news reported that could drive the stock up. The Denmark based clinical ...

View IO Biotech, Inc. IOBT stock quote prices, financial information, real-time forecasts, and company news from CNN.

IOBT Company Profile IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.

IO Biotech Inc. IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform.

IO Biotech files for the sale of up to 5.6M shares of common stock for holders May 23, 2025 4:17 PM ET IO Biotech, Inc. (IOBT) Stock By: Nivedita Hazra, SA News Editor Play (<1min) ...